------ Forwarded Message
From: Patti Loykasek
Date: Fri, 01 Feb 2008 11:18:26 -0800
Subject: Re: [Histonet] Re: Histonet Digest, Vol 51, Issue 2
I'll try to formulate a brief answer to the question of validating
antibodies. If you are doing IHC both CLIA and CAP have regulations that
involve validation of antibodies. These regulations cover Establishment and
Verification of Method Performance Specifications. The validation process
is designed to confirm the ability of the antibody to recognize the target
antigen in normal and diseased tissues where it is reasonably expected to
localize. And that there is not any obvious unexpected expression; in
other words, to determine its specificity and sensitivity.
To validate antibodies for IHC it's a multiple step process. First you would
need to determine the working titer, pretreatment, detection & chromogen
that you are going to use. Use your standard SOPS. Use a control that
contains the antigen in question plus some negative elements. You don't want
a control that is a high expressor or too low of an expresser at this point=2E
Once youšve determined your working parameters, you need to test the
antibody on normal tissue & diseased tissue that does & does not contain the
antigen. For example, if you are validating an antibody that is positive in
Lung carcinomas you would want to use lung carcinomas (should be positive=29,
& a variety of carcinomas, lymphomas, etc... That should be negative. You
may find that this antibody is positive in GI carcinoma, too & you would
want to document that & know what % of GI carcinomas are positive, Also, run
some normal tissues & assess their positive & negative rate. W compare our
findings with the published literature. You need to document all this work (
if you donšt document it, it didnšt happen). Excel or some other software is
good for documenting your findings. We have a template that we use for all
work ups (& a validation SOP).
Hope this helps. Good luck.
Patti Loykasek BS, HTL, QIHC
> does anyone validate antibody and how do you = do it?
> Con= fidentiality Notice: This email message, including any
> attachments, is for = the sole use of the intended recipient(s) and
> may contain confidential and = privileged information. Any
> unauthorized review, use, disclosure or distr= ibution is
> prohibited. If you are not the intended recipient, please cont= act
> the sender by reply email and destroy all copies of the original
> messag= e.
> Histonet mailing list
------ End of Forwarded Message
This e-mail message, including any attachments, is for the sole use of the
intended recipients and may contain privileged information. Any unauthorized
review, use, disclosure or distribution is prohibited. If you are not the intended
recipient, please contact the sender by e-mail and destroy all copies of the
original message, or you may call PhenoPath Laboratories, Seattle, WA U.S.A.
at (206) 374-9000.
Histonet mailing list